ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Results of Operations and Financial Condition

ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Results of Operations and Financial Condition
Item 9.01. Results of Operations and Financial Condition.

On March13, 2018, Aralez Pharmaceuticals Inc., a company formed under the laws of the Province of British Columbia, Canada (the “Company”), issued a press release announcing its results of operations for the quarter and full-year ended December31, 2017. The full text of such press release is furnished as Exhibit99.1 to this report and is incorporated herein by reference.

Item 9.01. Regulation FD Disclosures.

As previously announced, the Company will conduct a conference call today, Tuesday, March13, 2018 at 8:30 a.m.ET, to discuss its 2017 fourth quarter and full-year financial results and recent highlights. The presentation slides to be used during the call will be available on the “Investors” section of the Company’s website (http://www.aralez.com) under the “Presentations& Webcasts” tab beginning at 8:30 a.m.ET on Tuesday, March13, 2018. A question and answer session will follow the presentation. The conference call and the presentation slides will be simultaneously webcast on the “Investors” section of the Company’s website under the “Presentations& Webcasts” tab beginning at 8:30 a.m.ET on Tuesday, March13, 2018, and will remain available for future review for two weeks after the event. The information contained in, or that can be accessed through the Company’s website, is not a part of this filing.

Item 9.01. Financial Statements and Exhibits

(d)List of Exhibits

EXHIBIT NO.

DESCRIPTION

99.1

Press Release, dated March13, 2018, issued by Aralez Pharmaceuticals Inc.


Aralez Pharmaceuticals Inc. Exhibit
EX-99.1 2 a18-8111_1ex99d1.htm EX-99.1 Exhibit 99.1       ARALEZ ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS   -4Q 2017 Net Revenues Increased to $28.0 Million Versus $20.0 Million in the 4Q 2016- -Full-Year Net Revenues Increased to $105.9 Million Versus $54.3 Million in Full-Year 2016- -Provides 2018 Full-Year Financial Guidance-   Mississauga,…
To view the full exhibit click here

About ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ)

Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).

An ad to help with our costs